Cargando…

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors

BACKGROUND: Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) play a key role in tumour invasion and metastasis. High levels of both proteolytic enzymes are associated with poor prognosis in breast cancer patients. The purpose of this study was to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lampelj, Maja, Arko, Darja, Cas-Sikosek, Nina, Kavalar, Rajko, Ravnik, Maja, Jezersek-Novakovic, Barbara, Dobnik, Sarah, Dovnik, Nina Fokter, Takac, Iztok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Versita, Warsaw 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722926/ https://www.ncbi.nlm.nih.gov/pubmed/26834522 http://dx.doi.org/10.2478/raon-2014-0049

Ejemplares similares

Survival of Node-negative Breast Cancer Patients Treated at the University Medical Centre Maribor in the Period 2000–2009
por: Fokter Dovnik, Nina, et al.
Publicado: (2017)

Prognostic significance of uPA/PAI-1 level, HER2 status, and traditional histologic factors for survival in node-negative breast cancer patients
por: Dovnik, Nina Fokter, et al.
Publicado: (2016)

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)

Clinical features and their effect on outcomes of patients with triple negative breast cancer with or without lymph node involvement
por: Sobočan, Monika, et al.
Publicado: (2019)

The autoactivation of human single-chain urokinase-type plasminogen activator (uPA)
por: Torres-Paris, Constanza, et al.
Publicado: (2023)

Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation
por: Cunningham, Orla, et al.
Publicado: (2009)

Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer
por: Asuthkar, Swapna, et al.
Publicado: (2013)

Urokinase-type plasminogen activator (uPA) regulates invasion and matrix remodelling in colorectal cancer
por: Micalet, Auxtine, et al.
Publicado: (2023)

Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer
por: Pusina, Sadat
Publicado: (2018)

A Key Role for the Urokinase Plasminogen Activator (uPA) in Invasive Group A Streptococcal Infection
por: Sanderson-Smith, Martina L., et al.
Publicado: (2013)

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
por: de Witte, J H, et al.
Publicado: (1999)

Inhibition of urokinase plasminogen activator “uPA” activity alters ethanol consumption and conditioned place preference in mice
por: Al Maamari, Elyazia, et al.
Publicado: (2014)

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain
por: Merino, Paola, et al.
Publicado: (2017)

Gynaecological cancers and their cell lines
por: Skok, Kristijan, et al.
Publicado: (2021)

Comparison of Conservative Treatment of Cervical Intraepithelial Lesions with Imiquimod with Standard Excisional Technique Using LLETZ: A Randomized Controlled Trial
por: Cokan, Andrej, et al.
Publicado: (2021)

uPA-mediated plasminogen activation is enhanced by polyphosphate
por: Whyte, Claire S., et al.
Publicado: (2020)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
por: Mahmood, Niaz, et al.
Publicado: (2018)

Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA
por: Dreymann, Nico, et al.
Publicado: (2022)

The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type
Publicado: (1986)

A Pilot Study of Urokinase-Type Plasminogen Activator (uPA) Overexpression in the Brush Cytology of Patients with Malignant Pancreatic or Biliary Strictures
por: Gibbs, John F., et al.
Publicado: (2009)

Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK)
por: Santos, Nancy Dos, et al.
Publicado: (2007)

Increased expression of urokinase type plasminogen activator(u-PA), plasminogen activator inhibitor-1(PAI-1), and collagenases in Caco-2 cells infected by Salmonella typhimurium.
por: Park, C. G., et al.
Publicado: (1997)

In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)

Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
por: Godtfredsen, Nina S., et al.
Publicado: (2018)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

PAI-1, the Plasminogen System, and Skeletal Muscle
por: Rahman, Fasih Ahmad, et al.
Publicado: (2020)

Urokinase Plasminogen Activator Receptor (uPAR) and Plasminogen Activator Inhibitor-1 (PAI-1) Are Potential Predictive Biomarkers in Early Stage Oral Squamous Cell Carcinomas (OSCC)
por: Magnussen, Synnøve, et al.
Publicado: (2014)

Aggregation and retention of human urokinase type plasminogen activator in the yeast endoplasmic reticulum
por: Agaphonov, Michael O, et al.
Publicado: (2002)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
Publicado: (1984)

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
por: Knoop, A., et al.
Publicado: (1998)

Inquiry and Computer Program Onko-Online: 25 Years of Clinical Registry for Breast Cancer at the University Medical Centre Maribor
por: Arko, Darja, et al.
Publicado: (2019)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
por: Zhu, Ran, et al.
Publicado: (2022)

Is the Urokinase Plasminogen Activator/Plasminogen Activator Inhibitor-1 Ratio a Marker of Sonographic Septations in Pleural Infection?
por: Yasuma, Taro, et al.
Publicado: (2022)

Vitamin D and Ovarian Cancer: Systematic Review of the Literature with a Focus on Molecular Mechanisms
por: Dovnik, Andraž, et al.
Publicado: (2020)

Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients
por: Kotzsch, Matthias, et al.
Publicado: (2011)

Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator
por: Heynekamp, Justin J, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_ho1r2nvfq1bt07i3d66b5gupk3